Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 4:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 937–960 of 1,853 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Severe Mental Illness Clear all
Completed Phase 3 Interventional Results available

Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder

NCT05061706
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Lumateperone, Placebo
Drug
Lead sponsor
Intra-Cellular Therapies, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
17
States / cities
Little Rock, Arkansas • Rogers, Arkansas • Newport Beach, California + 14 more
Source: ClinicalTrials.gov public record
Updated May 9, 2025 · Synced Oct 16, 2026, 4:05 PM EDT
Terminated Not applicable Interventional Results available

Treatment of Depression With Connectivity Guided Robotically Delivered rTMS

NCT02802293
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
repetitive transcranial magnetic stimulation, robotic arm
Device
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 25, 2022 · Synced Oct 16, 2026, 4:05 PM EDT
Active, not recruiting Not applicable Interventional

EPI-MINN: Targeting Cognition and Motivation - National

NCT05877716
View directory record Official record
Conditions
Psychosis, Psychosis Nos/Other, Schizophrenia, Schizo Affective Disorder, Schizoaffective Disorder, Prodromal Schizophrenia, Schizophrenia Spectrum and Other Psychotic Disorders, Schizophreniform Disorders, Major Depression With Psychotic Features, Unspecified Psychosis, Bipolar Disorder
Interventions
Cognitive and Social Cognitive Training, Personalized Real-Time Intervention for Motivational Enhancement (PRIME) App, Early Psychosis Coordinated Specialty Care
Device · Behavioral · Other
Lead sponsor
University of Minnesota
Other
Eligibility
15 Years to 40 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 16, 2026, 4:05 PM EDT
Completed Phase 4 Interventional Results available

Study of the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Participants With Tardive Dyskinesia

NCT05859698
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depressive Disorder, Tardive Dyskinesia
Interventions
Valbenazine
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
18
States / cities
Bryant, Arkansas • Anaheim, California • Orange, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2026 · Synced Oct 16, 2026, 4:05 PM EDT
Completed Not applicable Interventional Results available

Illness Management and Recovery for Veterans With Severe Mental Illness

NCT00515671
View directory record Official record
Conditions
Schizophrenia, Schizo-affective Disorder
Interventions
Illness Management and Recovery, Problem Solving
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 15, 2021 · Synced Oct 16, 2026, 4:05 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Beyond Monoamines: The Role of the Nociceptin/Orphanin FQ Receptor in Major Depression

NCT05630963
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Aversive stimuli, PET radiotracer
Device · Drug
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 45 Years
Enrollment
228 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 21, 2025 · Synced Oct 16, 2026, 4:05 PM EDT
Completed Not applicable Interventional

Improving Diabetes Outcomes for Persons With Severe Mental Illness

NCT02053714
View directory record Official record
Conditions
Diabetes
Interventions
Diabetes self-management and education
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Oct 16, 2026, 4:05 PM EDT
Terminated No phase listed Observational

A Standard of Care Study of Patients With Major Depressive Disorder Who Have Had an Inadequate Response to a Selective Serotonin Reuptake/Serotonin-Norepinephrine Reuptake Inhibitor Antidepressant

NCT05109195
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Standard of Care (SOC)
Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 74 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
3
States / cities
San Francisco, California • Boston, Massachusetts • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 27, 2025 · Synced Oct 16, 2026, 4:05 PM EDT
Completed Phase 1 Interventional

A Study to Investigate the Antidepressant Mechanism-of-action of JNJ-42847922 in Participants With Major Depressive Disorder

NCT03374475
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
JNJ-42847922 20mg, JNJ-42847922 40mg, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
3
States / cities
San Diego, California • San Marcos, California • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 27, 2025 · Synced Oct 16, 2026, 4:05 PM EDT
Terminated Phase 3 Interventional Results available

Time to Remission of Depressive Symptoms With Combined SSRI and Ramelteon

NCT00642694
View directory record Official record
Conditions
Major Depressive Disorder, Insomnia
Interventions
Escitalopram, Ramelteon, Placebo
Drug · Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 26, 2019 · Synced Oct 16, 2026, 4:05 PM EDT
Completed Phase 2 Interventional

An Eight-Week Study Evaluating the Efficacy and Tolerability of Two Doses of SSR149415 in Outpatients With Major Depressive Disorder

NCT00358631
View directory record Official record
Conditions
Depressive Disorder
Interventions
SSR149415
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 64 Years
Enrollment
319 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 13, 2009 · Synced Oct 16, 2026, 4:05 PM EDT
Completed Phase 4 Interventional

Major Depressive Disorder Study In Adults

NCT00049972
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
paroxetine CR
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
646 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
71
States / cities
Birmingham, Alabama • Fairfield, Alabama • Mobile, Alabama + 63 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2017 · Synced Oct 16, 2026, 4:05 PM EDT
Terminated Phase 3 Interventional Results available

Quetiapine Extended Release (XR) Treatment of Major Depressive Disorder With Comorbid Generalized Anxiety Disorder

NCT00868374
View directory record Official record
Conditions
Major Depressive Disorder, Generalized Anxiety Disorder
Interventions
Quetiapine XR, Placebo
Drug
Lead sponsor
Keming Gao
Other
Eligibility
18 Years to 70 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 29, 2016 · Synced Oct 16, 2026, 4:05 PM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Brexpiprazole as Adjunctive Treatment in Elderly Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment

NCT01837797
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Placebo, Brexpiprazole 1 mg, Brexpiprazole 3 mg
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
65 Years and older
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
2
States / cities
National City, California • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Oct 17, 2018 · Synced Oct 16, 2026, 4:05 PM EDT
Completed Phase 2 Interventional Results available

Study Evaluating Desvenlafaxine Succinate Sustained-Release Tablets (DVS SR) In The Treatment Of Child and Adolescent Outpatients With Major Depressive Disorder

NCT00669110
View directory record Official record
Conditions
Depressive Disorder, Major Depressive Disorder
Interventions
Desvenlafaxine Succinate Sustained-Release Tablets (DVS SR)
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
7 Years to 18 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
9
States / cities
Little Rock, Arkansas • North Miami, Florida • Terre Haute, Indiana + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2021 · Synced Oct 16, 2026, 4:05 PM EDT
Recruiting No phase listed Observational

University of Iowa Interventional Psychiatry Service Patient Registry

NCT04480918
View directory record Official record
Conditions
Treatment Resistant Depression, Major Depressive Episode, Major Depression, Major Depressive Disorder, Bipolar Disorder, Bipolar Depression, Obsessive-Compulsive Disorder
Interventions
Electroconvulsive Therapy (ECT), Transcranial Magnetic Stimulation (TMS), Ketamine, Esketamine, Deep Transcranial Magnetic Stimulation (dTMS)
Device · Drug
Lead sponsor
Mark Niciu
Other
Eligibility
18 Years to 99 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2050
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Oct 16, 2026, 4:05 PM EDT
Withdrawn Phase 2 Interventional

The Effects of Psilocybin on Self-Focus and Self-Related Processing in Treatment Resistant MDD

NCT05381974
View directory record Official record
Conditions
Treatment-Resistant Major Depressive Disorder
Interventions
Psilocybin
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 55 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 24, 2024 · Synced Oct 16, 2026, 4:05 PM EDT
Completed Not applicable Interventional

Thinking Skills for Work in Severe Mental Illness

NCT01926613
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Major Depression, Bipolar Disorder, Anxiety Disorder
Interventions
Thinking Skills for Work Program, Supported Employment
Behavioral
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
2
States / cities
Chicago, Illinois • Manchester, New Hampshire
Source: ClinicalTrials.gov public record
Updated Aug 21, 2013 · Synced Oct 16, 2026, 4:05 PM EDT
Completed Phase 2 Interventional

A Clinical Trial of Adjunctive and Monotherapy PRAX-114 in Participants With Major Depressive Disorder

NCT04969510
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
10 mg PRAX-114, 20 mg PRAX-114, 40 mg PRAX-114, 60 mg PRAX-114, Placebo
Drug
Lead sponsor
Praxis Precision Medicines
Industry
Eligibility
18 Years to 65 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
23
States / cities
Lafayette, California • Lemon Grove, California • Oceanside, California + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2022 · Synced Oct 16, 2026, 4:05 PM EDT
Completed Not applicable Interventional

Physician-Initiated Stop-Smoking Program for Patients Receiving Treatment for Early-Stage Cancer

NCT00002520
View directory record Official record
Conditions
Bladder Cancer, Breast Cancer, Colorectal Cancer, Head and Neck Cancer, Lung Cancer, Lymphoma, Prostate Cancer, Testicular Germ Cell Tumor, Tobacco Use Disorder, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
nicotine, Usual Care
Drug · Behavioral
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
19 Years to 120 Years
Enrollment
434 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1990
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 15, 2023 · Synced Oct 16, 2026, 4:05 PM EDT
Completed Phase 2 Interventional Results available

Rapid Antidepressant Effects of Yohimbine in Major Depression

NCT00078715
View directory record Official record
Conditions
Depression, Involutional, Major Depresssion
Interventions
Yohimbine hydrochloride, Placebo
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 65 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 29, 2019 · Synced Oct 16, 2026, 4:05 PM EDT
Completed Phase 2 Interventional Results available

Incomplete Response in Late-Life Depression: Getting to Remission With Buprenorphine

NCT02176291
View directory record Official record
Conditions
Depression, Major Depressive Disorder
Interventions
Buprenorphine, Placebo
Drug
Lead sponsor
Jordan F. Karp
Other
Eligibility
50 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 29, 2018 · Synced Oct 16, 2026, 4:05 PM EDT
Recruiting Not applicable Interventional

Mindful Self-Compassion for Anxiety Disorders and Depression

NCT05671419
View directory record Official record
Conditions
Anxiety Disorders, Generalized Anxiety Disorder, Social Anxiety Disorder, Social Phobia, Panic Disorder, Agoraphobia, Major Depressive Disorder
Interventions
Mindful Self-Compassion
Behavioral
Lead sponsor
Georgetown University
Other
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 16, 2026, 4:05 PM EDT
Completed Phase 3 Interventional Results available

An Open-label Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder

NCT05061719
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Lumateperone
Drug
Lead sponsor
Intra-Cellular Therapies, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
812 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
40
States / cities
Phoenix, Arizona • Bentonville, Arkansas • Little Rock, Arkansas + 35 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2025 · Synced Oct 16, 2026, 4:05 PM EDT